Kimberly Guibone, DNP, ACNP-BC, FACC

This is further generation of evidence that may encourage more likelihood of the low-to-intermediate-risk patients selecting TAVR with a good understanding, and with a likelihood of good outcomes and, hopefully, durability, which we hope to see. This generation of evidence is very helpful for shared decision-making, particularly now where the less-invasive nature of TAVR makes it more appealing, but not necessarily quite the right decision for everyone.